ISA-t...in the news:
Isotechnika Receives New Zealand Patent For ISA(TX)247
EDMONTON, Nov. 16 /CNW/ - Dr. Robert Foster, Chairman and CEO, of
Isotechnika Inc. is pleased to announce that the Company has received the
Official Issue Notification from the New Zealand Patent and Trademark Office
regarding the Company's novel immunosuppressant compound, ISA(TX)247. This
application has been issued New Zealand Patent No. 502362, titled, "Deuterated
Cyclosporine Analogs and their uses as immunomodulating agents."
"We are very pleased with the issuance of this Patent", states Dr.
Randall Yatscoff, President and COO. "We look forward to this patent issuing
throughout the world in the other countries in which we have filed."
"The issuance of this patent is an important milestone for the Company.
It provides confidence to the market regarding the intellectual property
protection regarding our technology. It further strengthens our position for
any future licensing negotiations", states Joseph Koziak, Executive Vice
President.
Isotechnika is a life sciences company headquartered in Edmonton, Alberta
developing novel drugs and diagnostic products. Its lead compound, ISA(TX)247
is a novel immunosuppressive drug that can be used for prevention of organ
rejection after transplantation and for treatment of autoimmune diseases such
as rheumatoid arthritis and psoriasis. This drug is now in Phase 2 clinical
trials in Canada and the United States. Based upon the studies completed to
date, ISA(TX)247 demonstrates superior efficacy and reduced toxicity when
compared with presently used medications for organ transplantation such as
Cyclosporine. Current annual worldwide sales of Cyclosporine are in excess of
$1.4 billion USD. |
